Zanidatamab, a Novel Bispecific Antibody, for Locally Advanced or Metastatic HER2-Expressing/HER2-Amplified Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Lancet Oncol 2022 Dec 01;23(12)1558-1570, F Meric-Bernstam, M Beeram, E Hamilton, DY Oh, DL Hanna, YK Kang, E Elimova, J Chaves, R Goodwin, J Lee, L Nabell, SY Rha, J Mayordomo, A El-Khoueiry, S Pant, K Raghav, JW Kim, A Patnaik, T Gray, R Davies, MA Ozog, J Woolery, KW LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.